PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
about
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
PQR309 Is a Novel Dual PI3K/mT ...... nt and in Combination Therapy.
@en
PQR309 Is a Novel Dual PI3K/mT ...... nt and in Combination Therapy.
@nl
type
label
PQR309 Is a Novel Dual PI3K/mT ...... nt and in Combination Therapy.
@en
PQR309 Is a Novel Dual PI3K/mT ...... nt and in Combination Therapy.
@nl
prefLabel
PQR309 Is a Novel Dual PI3K/mT ...... nt and in Combination Therapy.
@en
PQR309 Is a Novel Dual PI3K/mT ...... nt and in Combination Therapy.
@nl
P2093
P50
P1476
PQR309 Is a Novel Dual PI3K/mT ...... ent and in Combination Therapy
@en
P2093
Alberto J Arribas
Anastasios Stathis
Andrea Rinaldi
Barbara Dossena
Chiara Tarantelli
Davide Rossi
Denise Rageot
Doriano Fabbro
Elena Bernasconi
Eugenio Gaudio
P304
P356
10.1158/1078-0432.CCR-17-1041
P407
P50
P577
2017-10-24T00:00:00Z